

1954-352
MJM:smt

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
Barry Forman, et al.)
Serial No. 09/927,341) Examiner: To be assigned
Filed: August 13, 2001) Group Art Unit: To be assigned
For: THE ANTI-NEOPLASTIC AGENT ET-743
INHIBITS TRANS ACTIVATION BY SXR)

INFORMATION DISCLOSURE STATEMENT


Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Under the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98,
Applicant submits herewith copies of publications that the Office
may wish to consider in examination of the subject application.
The publications are listed on the attached form PTO-1449.

Respectfully submitted,

By


Michael J. Moran
Attorney for Applicants
Registration No. 42,013
ROTHWELL, FIGG, ERNST & MANBECK, p.c.
Suite 701-E, 555 13th Street, N.W.
Washington, D.C. 20004
Telephone: (202) 783-6040

Enclosure(s): references(44)
1954-352.ids

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	5	Attorney Docket Number	1954-352

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		5,217,867		Evans et al.	Jun. 8, 1993
		5,571,696		Evans et al.	Nov. 5, 1996
		5,710,004		Evans et al.	Jan. 20, 1998
		5,736,157		Williams	Apr. 7, 1998
		5,906,920		Evans et al.	May 25, 1999
		5,702,914		Evans et al.	Dec. 30, 1997
		5,071,773		Evans et al.	Dec. 10, 1991


FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee of Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³ Code	Number ⁴	Kind ⁵ (if known)			
			WO 97/35195		The Salk Institute for Biological Studies	Sept. 25, 1997	
			WO 94/18346		The Board of Regents of the University of Texas System	Aug. 18, 1994	

Examiner Signature _____ Date Considered _____


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	5	Attorney Docket Number	1954-352
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		Blumberg, B., et al., "SXR, a novel steroid and xenobiotic-sensing nuclear receptor," <u>Genes & Development</u> , Vol. 12, pp. 3195-3205, 1998.			
		Xie, W., et al., "Humanized xenobiotic response in mice expressing nuclear receptor SXR," <u>Nature</u> , Vol. 406, pp. 435-439, July 27, 2000.			
		Bertilsson, G., et al., "Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 95, pp. 12208-12213, October 1998.			
		Forman, B.M., et al., "Unique Response Pathways Are Established by Allosteric Interactions among Nuclear Hormone Receptors," <u>Cell</u> , Vol. 81, pp. 541-550, May 19, 1995.			
		Lehmann, J.M., et al., "The Human Orphan Nuclear Receptor PXR is Activated by Compounds That Regulate CYP3A4 Gene Expression and Cause Drug Interactions," <u>J. Clin. Invest.</u> , Vol. 102, No. 5, pp. 1016-1023, September 1998.			
		Shen, D.W., et al., "Human Multidrug-Resistant Cell Lines: Increased <i>mdr1</i> Expression Can Precede Gene Amplification," <u>Science</u> , Vol. 232, pp. 643-645, May 2, 1986.			
		Forman, B., et al., "15-Deoxy- $\Delta^{12,14}$ -Prostaglandin J2 Is a Ligand for the Adipocyte Determination Factor PPAR γ ," <u>Cell</u> , Vol. 83, pp. 803-812, December 1, 1995.			
		Synold, et al., "The Orphan Nuclear Receptor SXR Coordinately regulates Drug Metabolism and Efflux," <u>Nature Medicine</u> , Vol. 7, No. 5, pp 584-590, May 2001.			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.


INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	5	Attorney Docket Number	1954-352
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		Kliewer, S.A., et al., "An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway," <u>Cell</u> , Vol. 92, 73-82, January 9, 1998.			
		Apfel, R., et al., "A Novel Orphan Receptor Specific for a Subset of Thyroid Hormone-Responsive Elements and Its Interaction with the Retinoid/Thyroid Hormone Receptor Subfamily," <u>Molecular and Cellular Biology</u> , Vol. 14, No. 10, pp. 7025-7035, October 1994.			
		Hong, H., et al., "GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 4948-4952, May 1996.			
		Brown, M.S., et al., "The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor," <u>Cell</u> , Vol. 89, pp. 331-340, May 2, 1997.			
		Gottesman, M.M., et al., "Biochemistry of Multidrug Resistance Mediated by the Multidrug Transporter," <u>Annu. Rev. Biochem.</u> , Vol. 62, pp. 385-427, 1993.			
		Boehm, M.F., et al., "Design and Synthesis of Potent Retinoid X Receptor Selective Ligands That Induce Apoptosis in Leukemia Cells," <u>J. Med. Chem.</u> , Vol. 38, pp. 3146-3155, 1995.			
		Noonan, K.E., et al., "Quantitative analysis of <i>MDR1</i> (multidrug resistance) gene expression in human tumors by polymerase chain reaction," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 87, pp. 7160-7164, September 1990.			
Examiner Signature				Date Considered	


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	4	of	5	Attorney Docket Number	1954-352

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Forman, B.M, et al., "The orphan nuclear receptor LXR α is positively and negatively regulated by distinct products of mevalonate metabolism," <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp. 10588-10593, September 1997.	
		Glass, C.K., et al., "Nuclear receptor coactivators," <u>Curr. Opin. Cell Bio.</u> , Vol. 9, pp. 222-232, 1997.	
		Mangelsdorf, D.J., et al., "The RXR Heterodimers and Orphan Receptors," <u>Cell</u> , Vol. 83, pp. 841-850, December 15, 1995.	
		Janowski et al., "An oxysterol signalling pathway mediated by the nuclear receptor LXR α ," <u>Nature</u> , 383:728-731 (1996).	
		Kenneth L. Rinehart, "Antitumor Compounds From Tunicates", <u>Med. Res. Rev.</u> , Vol. 20, pp 1-27, 2000.	
		Izbicka, et al., "In Vitro Antitumor Activity of the Novel Marine Agent, Ecteinascidin-743 (ET-743, NSC-648766) Against Human Tumors Explanted From Patients", <u>Annals of Oncology</u> , Vol. 9, pp 981-987, 1998.	
		Hendriks, et al., "High Antitumour Activity of ET743 Against Human Tumour Xenografts from Melanoma, Non-Small-Cell Lung and Ovarian Cancer, <u>Annals of Oncology</u> , Vol. 10, pp 1233-1240, 1999.	
		Zewail-Foote, et al., "Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA Toward the Major Groove", <u>Journal Of Medicinal Chemistry</u> , Vol. 42, No. 14, pp 2493-2497, 1999.	
		Pommier, et al., "DNA Sequence- and Structure-Selective Alkylation of Guanine N2 in the DNA Minor Groove by Ecteinascidin 743, A Potent...", <u>Biochemistry</u> , 35, pp 13303-13309, 1996.	
		Takebayashi, et al., "Poisoning of Human DNA Topoisomerase I...", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 96, pp. 7196-7201, June 1999.	
		Bonfanti, et al., "Effect of ecteinascidin-743 on the Interaction...", <u>Anti-Cancer Drug Design</u> , 14, pp 179-186, 1999.	
		Jin, et al., "Ecteinascidin 743, A Transcriptin-targeted Chemotherapeutic...", <u>PNAS</u> , Vol. 97, No. 12, pp. 6775-6779, June 6, 2000.	
		Minuzzo, et al., "Interference of Transcriptional Activation by the Antineoplastic...", <u>PNAS</u> , Vol. 97, pp. 6780-6784, June 6, 2000.	
		Forman, et al., "Androstane metabolites bind to and deactivate the nuclear receptor CAR- β ", <u>Nature</u> , Vol. 395, pp 612-615, October 8, 1998.	
		Pallis, et al., "P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic...", <u>Blood</u> , Vol. 95, No. 9, pp 2897-2904, May 1, 2000.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT				<i>Complete if Known</i>	
				Application Number	09/927,341
				Filing Date	August 13, 2001
				First Named Inventor	Barry Forman, et al.
				Group Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	5	of	5	Attorney Docket Number	1954-352
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		Kliewer, et al., "Orphan Nuclear Receptors: Shifting Endocrinology into Reverse", <u>Science</u> , Vol. 284, pp 757-760, April 30, 1999.			
		Forman, et al., "Hypolipidemic drugs, polyunsaturated fatty acids,...", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 94, pp 4312-4317, April, 1997.			
		Wang, et al., "Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR", <u>Molecular Cell</u> , Vol. 3, pp 543-553, May, 1999.			
		Wacher, et al., "Overlapping Substrate Specificities and Tissue Distribution...", <u>Molecular Carcinogenesis</u> , 13:, pp 129-134, 1995.			
		Schuetz, et al., "Modulators and Substrates of P-glycoprotein and Cytochrome...", <u>Molecular Pharmacology</u> , 49:, pp 311-318, 1996			
Examiner Signature				Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.